Fears raised over pilot test reliability

Andreas Lubitz

Potential weaknesses highlighted in airlines’ fitness checks

insulin vials
©Jacob Ehrbahn

Insulin: moving the needle

One of the most lucrative pharma markets is about to change

Actavis lab

Actavis rewrites ‘big pharma’ playbook

Are big, lean dealmakers running out of targets?

The last bell tolls for the lethal injection

Now pharmaceutical companies shun association with state-sanctioned killing, writes Anjana Ahuja

Drugs groups unite to mine genetic data

Groups to join 100,000 Genomes Project

Venture capitalist Jon Moulton has invested in biotech company RedX Pharma

Moulton-backed RedX Pharma to list on Aim

UK life science industry shows sign of life beyond southeast

Ranbaxy pledges to regain US trust

Sun Pharma wins go-ahead to complete takeover of troubled group

The value of a life is not about cost

Perhaps governments should finance the payment of a national licence fee for drugs

Tenet/United Surgical: knife edge

No one wants to pay for long hospital stays

Pharmacyclics boss reaps $3.6bn from bid

AbbVie $21bn takeover delivers almost $4bn to executives

Silicon Valley lands on big pharma’s turf

Tech industry’s turn to healthcare unsettles drugmakers

Samsung steps up digital health drive

South Korean group aims to build ties with US start-ups

Apple puts clinical research tool in your pocket

Innovation helps scientists plug in to data from iPhones

Cannabis companies: puffed up

Dude, investing in pot is such a drag

Biogen’s Alzheimer’s drug shows early promise

US biotech group’s shares rise 7% after experimental treatment slows rate of cognitive decline

Matching surplus medicine with need

Supply chain management cuts waste in foreign aid

Fund to fight drug-resistant infections

Focus on low and middle-income countries

Valeant bid knocks Endo out of Salix race

Offer narrowly exceeds cash-and-shares bid from Dublin group

Life Time Fitness agrees $4bn buyout

Leonard Green and TPG joined in deal by fitness group’s chairman

Valeant/Salix: resistance is futile

If Mike Pearson wants to pay more than necessary to clinch a deal, he will encounter little resistance


More FT Twitter accounts